☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Inhibitor Program
AbbVie Exercises its Option to License Morphosys' αvβ6 Integrin Inhibitor Program for Fibrotic Disease
August 25, 2020
AbbVie Licenses Lupin's MALT1 Inhibitor Program- for $977M
December 27, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
